A detailed history of Rhenman & Partners Asset Management Ab transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 178,284 shares of INMB stock, worth $1.57 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
178,284
Previous 178,284 -0.0%
Holding current value
$1.57 Million
Previous $2.01 Million 4.33%
% of portfolio
0.2%
Previous 0.2%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$6.61 - $10.9 $847,957 - $1.4 Million
128,284 Added 256.57%
178,284 $1.21 Million
Q3 2023

Nov 09, 2023

SELL
$6.61 - $10.9 $847,957 - $1.4 Million
-128,284 Reduced 71.95%
50,000 $338,000
Q2 2023

Aug 11, 2023

BUY
$6.5 - $10.09 $1.16 Million - $1.8 Million
178,284 New
178,284 $1.62 Million

Others Institutions Holding INMB

About Inmune Bio, Inc.


  • Ticker INMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,946,000
  • Market Cap $158M
  • Description
  • INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...
More about INMB
Track This Portfolio

Track Rhenman & Partners Asset Management Ab Portfolio

Follow Rhenman & Partners Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.